Brigatinib / Brigatinib (Brigatinib) role and efficacy

Brigatinib/Brigatinib is an anti-tumor agent, which can also be called a variety of caseins including anaplastic lymphoma kinase (ALK). Inhibitor of amino acid kinase, treatment of ALK-positive metastatic non-small cell lung cancer (designated as an orphan drug by the U.S. Food and Drug Administration for the treatment of ALK-positive, c-oncogene-1 [ros-1]-positive or epidermal growth factor receptor [EGFR] mutation-positive non-small cell lung cancer).

Anaplastic lymphoma kinase-positive metastatic NSCLC cancer (ALK+NSCLC) accounts for only 3-5% of NSCLC cancer cases. ALK-related cases of non-small cell lung cancer are associated with the presence of the fusion gene EML4-ALK, which fuses the ALK protein with the correct formation of microtubules in echinodermal cells, microtubule-associated protein-like-4. The presence of abnormal fusion proteins leads to abnormal signaling, which triggers increased cell growth, proliferation, and survival. Crizotinib is suitable for treating such cases, but the presence of ALK kinase domain mutations can confer resistance to treatment. Therefore, brigatinib is suitable for the treatment of ALK+ NSCLC patients who are intolerant to crizotinib.

This original drug is marketed in China under the name brigatinib, and has entered the scope of Class B medical insurance. Specifications The price of 30mg*14 tablets*2 tablets per box may be around 8,000 yuan, which is relatively expensive. Currently, there are relatively cheap generic brigatinib drugs on the market overseas. Their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of a box of 90mg*30 tablets produced by a Bangladesh pharmaceutical factory is around 2,000 yuan (the price may fluctuate due to exchange rates).